April 20th, 2015
Selections from Richard Lehman’s Literature Review: April 20th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the efficacy and safety of both alirocumab and evolocumab in reducing lipids and CV events, survival and outcomes following bioprosthetic vs. mechanical mitral valve replacement, and more.
August 31st, 2014
Preliminary Outcomes Results For PCSK9 Inhibitor
Larry Husten, PHD
Amid a slew of new data demonstrating yet again that PCSK9 inhibitors lower LDL cholesterol—drastically and in a wide variety of different patient populations—data from one trial offers the first suggestion that the drugs may in fact improve cardiovascular outcomes. But the analysis, the authors cautioned, is a post-hoc analysis of a trial neither designed nor […]
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?